PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2107771
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2107771
U.S. Elastomeric Infusion Pumps Market is estimated to be valued at USD 231.8 Mn in 2026 and is expected to reach USD 389.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 231.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.80% | 2033 Value Projection: | USD 389.7 Mn |
The U.S. elastomeric infusion pumps market includes various products such as variable rate elastomeric pumps and continuous rate elastomeric pumps which are used for the treatment of various indication such as oncology, post- operative care, general medicine, and others. The elastomeric infusion pumps are used to deliver the medication through intravenous route through IV line, the medication prescribed is filled in the chamber and the pressure is applied to the balloon for delivery of medication.
The increasing usage of antibiotics and other anti-infective drugs for the treatment of infectious diseases is expected to drive the segment growth over the forecast period
For instance, according to the Report of Centers for Disease Control and Prevention, in 2016, 270.2 million antibiotic prescriptions were written in the U.S. Increasing application of elastomeric infusion pumps in outpatient parenteral antimicrobial therapy is expected to boost the growth of the market
The increasing incidence of chronic blood diseases such as blood cancers which include leukemia, lymphoma, and myeloma or blood disorder such as anemia, bleeding disorders such as blood clots and hemophilia is expected to drive the segment growth over the forecast period.
According to the Centers for Disease Control and Prevention (CDC) in 2019, the Sickle Cell Disease (SCD) affects around 100,000 Americans each year. Moreover, according to Leukemia & Lymphoma Society, it was estimated that around 172,910 people in the U.S. were expected to be diagnosed with the leukemia, lymphoma or myeloma in 2017.
Key features of the study